{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.2","upperLimit":"43.4","value":"26.6"}]}],"title":"At 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.2","upperLimit":"43.4","value":"26.6"}]}],"title":"At 2 year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Estimated by cumulative incidence method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.\n\ntherapeutic allogeneic lymphocytes: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (DLI)"}],"paramType":"NUMBER","populationDescription":"Patients received at least one DLI treatment.","reportingStatus":"POSTED","timeFrame":"At 1 year and 2 year","title":"Rate of Chronic GVHD (cGVHD)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}